ATMA Journey Centers offers psychedelic training to physicians and prescribers

Canadian physicians and prescribing physicians can now enroll in a psychedelics training program developed by ATMA Journey Centers, a company that has gained experience by providing hands-on protocol experience Psilocybin-assisted therapy for palliative care patients and will next conduct clinical trials on MDMA-assisted therapy.

The offer is aimed at Alberta as a province new legal therapeutic framework calls on doctors and psychiatrists to assess whether patients are candidates for psychedelic treatment.

“There are only a handful of physicians and psychiatrists across Canada who have clinical experience working with psilocybin or MDMA, drugs that can be relieved of ketamine day and night, for example,” said CMO and psychiatrist Dr. Ravi Bains.

He believes that understanding the therapeutic effects of psychedelics “is critical to the role that physicians should play in the Alberta framework.”

Founder and Co-CEO David Harder added that the Alberta regulations “clearly state the need for education and training of all practitioners involved in psychedelics-assisted therapy, including physicians and psychiatrists” where ATMA intends to to become a leading training provider Supporting the regulatory framework.

“We believe that as more and more patients will come to them, ask questions, and want to be referred for these treatments, physicians and prescribers need a thorough understanding of these drugs,” Harder concluded.

The course, which is eligible for Continuing Medical Education (CME) credits, is now open for registration and will begin in mid-April.

Intensive program by Zach Leary & The Microdose

The highly experienced Zachary Leary – yes, Timothy’s adopted son – is launching an intensive program in psychedelic studies, supported by his new partner media company, Microdose Psychedelic Insights.

Zach has offered psychedelic therapy to nearly 100 people and over 50…